Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
On Friday, Merck & Co Inc (NYSE:MRK) agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
默沙東公司於週五同意從私人持有的Curon生物製藥公司收購CN201，這是正在臨床研究的針對b細胞相關疾病的 bispecific antibody。
"We continue to identify opportunities to expand and diversify our pipeline," said Dr. Dean Y. Li, president of Merck Research Laboratories. "Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and autoimmune diseases."
「我們繼續尋找擴大和多元化我們的流水線的機會，」默沙東研究實驗室總裁德恩Y. 李博士表示。 「早期的臨床數據已經提供了CN201具有潛力通過靶向和清除循環和組織b細胞來治療一系列惡性和自身免疫性疾病的強有力證據。」
Merck will acquire full global rights to CN201 for an upfront payment of $700 million in cash.
默沙東將以現金70000萬美元的前期費用全球收購CN201的所有權利。
Curon is also eligible to receive up to $600 million in milestone payments.
Curon還有資格獲得最高60000萬美元的里程碑獎金。
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 trials for relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia, respectively.
CN201目前正在進行1期和1b/2期試驗，用於復發或難治的非何傑金淋巴瘤和b細胞急性淋巴細胞白血病的治療。
Merck plans to evaluate CN201 as a treatment for B-cell malignancies and investigate its potential for autoimmune diseases.
默沙東計劃將CN201作爲b細胞惡性腫瘤的治療方案，並調查其在自身免疫性疾病中的潛力。
The transaction is expected to close in the third quarter of 2024. Merck expects to record a pre-tax charge of approximately $750 million, or approximately $0.28 per share, to be included in adjusted results.
本次交易預計將於2024年第三季度關閉。默沙東預計將在調整後的結果中錄得約7,500萬美元的稅前費用，或約每股0.28美元。
Also Read: Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects.
此外閱讀：由於無效的結果和副作用，默克停止肺癌研究的Keytruda組合。
William Blair writes that the deal is relevant to Cullinan Therapeutics Inc.'s (NASDAQ:CGEM) CLN-978, which is expected to enter clinical trials in systemic lupus erythematosus and rheumatoid arthritis.
William Blair表示，本次交易與Cullinan Therapeutics Inc. (NASDAQ: CGEM)的CLN-978有關，並且預計後者將進入系統性紅斑狼瘡和類風溼性關節炎的臨床試驗。
CN201 is a CD19xCD3 bispecific, and the analyst says the deal supports its potential in treating autoimmune diseases. The analyst also highlighted the appealing valuation of Cullinan, which is currently valued at under $300 million.
CN201是CD19xCD3的bispecific，分析師表示，該交易支持其在治療自身免疫性疾病方面的潛力。分析師還強調了Cullinan的吸引力估值，目前估值不到3億美元。
As competition intensifies in the CD19 autoimmune sector, William Blair sees less rivalry in the CD19 bispecific arena than cell therapies, presenting a substantial opportunity for Cullinan.
隨着CD19自身免疫領域的競爭加劇，William Blair認爲，在CD19 bispecific領域中的競爭相對較小，而該領域相對於細胞療法來說具有很大的機會，這爲Cullinan提供了巨大的機遇。
The analyst reiterates the Outperform rating on Cullinan shares.
分析師重申對Cullinan股票的跑贏市場評級。
Price Action: CGEM stock is up 3.66% at $16.98, and MRK stock is up 0.31% at $114.27 at the last check on Friday.
在上週五的最後檢查時，CGEM股票上漲3.66%，報16.98美元，MRk股票上漲0.31%，報114.27美元。
- Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
- 銀休特的胰島素泵製造商成長催化劑預計將在2025年提高收益：分析師
Photo Courtesy Merck
照片由默克提供。